PURPOSE: Some patients with rhabdomyosarcoma (RMS) achieve less than a complete response (CR) despite receiving all planned therapy. We assessed the impact of best response at the completion of all therapy on patient outcome. PATIENTS AND METHODS: We studied 419 clinical group III participants who completed all protocol therapy without developing progressive disease for Intergroup Rhabdomyosarcoma Study (IRS) IV. Response (complete resolution [CR], partial response [PR; > or = 50% decrease], or no response [NR; < 50% decrease and < 25% increase]) was determined by radiographic measurement and categorized by the best response. RESULTS: At the end of therapy, 341 participants (81%) achieved a best response of CR and 78 (19%) had a best response of PR/NR. Five-year failure-free survival was similar for participants achieving CR (80%) and PR/NR (78%). After adjustment for age, nodal status, primary site, and histology, there was no significant indication of lower risk of failure (hazard ratio [HR], 0.77; 95% CI, 0.46 to 1.27; P = .3) nor death (HR, 0.63; 95% CI, 0.36 to 1.09; P = .1) for CR versus PR/NR participants. Seventeen participants with a best response of PR/NR had surgical procedures; eight (50%) of 16 with available pathology reports had residual viable tumor and only three achieved a complete resection. Resection of residual masses was not associated with improved outcome. CONCLUSION: CR status at the end of protocol therapy in clinical group III participants was not associated with a reduction of disease recurrence and death. Aggressive alternative therapy may not be warranted for RMS patients with a residual mass at the end of planned therapy.
PURPOSE: Some patients with rhabdomyosarcoma (RMS) achieve less than a complete response (CR) despite receiving all planned therapy. We assessed the impact of best response at the completion of all therapy on patient outcome. PATIENTS AND METHODS: We studied 419 clinical group III participants who completed all protocol therapy without developing progressive disease for Intergroup Rhabdomyosarcoma Study (IRS) IV. Response (complete resolution [CR], partial response [PR; > or = 50% decrease], or no response [NR; < 50% decrease and < 25% increase]) was determined by radiographic measurement and categorized by the best response. RESULTS: At the end of therapy, 341 participants (81%) achieved a best response of CR and 78 (19%) had a best response of PR/NR. Five-year failure-free survival was similar for participants achieving CR (80%) and PR/NR (78%). After adjustment for age, nodal status, primary site, and histology, there was no significant indication of lower risk of failure (hazard ratio [HR], 0.77; 95% CI, 0.46 to 1.27; P = .3) nor death (HR, 0.63; 95% CI, 0.36 to 1.09; P = .1) for CR versus PR/NR participants. Seventeen participants with a best response of PR/NR had surgical procedures; eight (50%) of 16 with available pathology reports had residual viable tumor and only three achieved a complete resection. Resection of residual masses was not associated with improved outcome. CONCLUSION:CR status at the end of protocol therapy in clinical group III participants was not associated with a reduction of disease recurrence and death. Aggressive alternative therapy may not be warranted for RMS patients with a residual mass at the end of planned therapy.
Authors: W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: S S Donaldson; J Meza; J C Breneman; W M Crist; F Laurie; S J Qualman; M Wharam Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: J H Visser; G Wessels; P B Hesseling; I Louw; E Oberholster; E P Mansvelt Journal: Pediatr Hematol Oncol Date: 2001 Apr-May Impact factor: 1.969
Authors: Marcus L Quek; Vannita Simma-Chiang; John P Stein; Jacek Pinski; David I Quinn; Donald G Skinner Journal: Expert Rev Anticancer Ther Date: 2005-10 Impact factor: 4.512
Authors: Megan Burke; James R Anderson; Simon C Kao; David Rodeberg; Stephen J Qualman; Suzanne L Wolden; William H Meyer; Philip P Breitfeld Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Beverly Raney; Julie Stoner; James Anderson; Richard Andrassy; Carola Arndt; Ken Brown; William Crist; Harold Maurer; Stephen Qualman; Moody Wharam; Eugene Wiener; William Meyer; Andrea Hayes-Jordan Journal: J Pediatr Surg Date: 2010-11 Impact factor: 2.545
Authors: David A Rodeberg; Moody D Wharam; Elizabeth R Lyden; Julie A Stoner; Kenneth Brown; Suzanne L Wolden; Charles N Paidas; Sarah S Donaldson; Douglas S Hawkins; Sheri L Spunt; Carola A Arndt Journal: Int J Cancer Date: 2014-12-10 Impact factor: 7.396
Authors: A Yuriko Minn; Elizabeth R Lyden; James R Anderson; Lynn Million; Carola A Arndt; Kenneth Brown; Douglas S Hawkins; Sarah S Donaldson Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins Journal: Eur J Cancer Date: 2013-12-18 Impact factor: 9.162
Authors: Timothy B Lautz; Yueh-Yun Chi; Jing Tian; Abha A Gupta; Suzanne L Wolden; Jonathan C Routh; Dana L Casey; Roshni Dasgupta; Douglas S Hawkins; David A Rodeberg Journal: Int J Cancer Date: 2020-02-15 Impact factor: 7.396